Type I interferon gene

The "Type I interferon genes" refer collectively to a cluster of genes encoding type I interferons, a subset of cytokines involved in antiviral defense, immune regulation, and modulation of cell proliferation and inflammation[7][1][2]. In humans, this gene family includes IFN-α subtypes (IFNA1, IFNA2, etc.), IFN-β (IFNB1), IFN-ε, IFN-κ, and IFN-ω, among others, located primarily at chromosome 9p21.3[7]. These genes are transcribed and translated into type I interferon proteins, which exert their biological effects by binding a shared heterodimeric cell-surface receptor (IFNAR1 and IFNAR2) and activating downstream Janus kinase (JAK)–STAT signaling[1][2][3][7]. The gene products (type I interferons) mediate broad immunological functions, including the induction of antiviral states in cells, modulation of innate and adaptive immune responses, and direct antiproliferative effects[1][2][8]. While the gene locus plays a fundamental biological role, it is not a typical direct therapeutic target; therapeutics instead target the cytokine products (e.g., recombinant interferon alpha or beta) or the type I interferon receptor. Additional clarification: - The actual therapeutic targets in medicine are typically the protein products of these genes (type I interferons such as IFN-α, IFN-β) or their receptor (the Type I interferon receptor, IFNAR)[3][5]. - Drugs such as recombinant interferon-alpha and interferon-beta are used clinically, but these act as agonists/mimetics of the proteins, not at the level of gene targeting[5]. - No drugs target the "Type I interferon genes" directly in current clinical practice. - The gene cluster is relevant for research, especially in understanding immune pathophysiology and genetic predispositions[7][8]. Summary of correction: - The entry "Type I interferon genes" is a gene family, not a canonical drug target (such as receptor, enzyme, transporter, etc.). The canonical targets for drug development are either the type I interferons themselves (e.g., interferon alpha, beta) as biotherapeutic agents, or the Type I interferon receptor (IFNAR1/IFNAR2) as the pharmacological target.

Other names

Type I IFN genesIFN-I genesIFNA genesIFNB1 geneIFNE geneIFNW1 geneIFNK gene